Literature DB >> 9288044

Assessment of UK practice for management of acute childhood idiopathic thrombocytopenic purpura against published guidelines.

P H Bolton-Maggs1, I Moon.   

Abstract

BACKGROUND: Guidelines for management of acute immune thrombocytopenic purpura (ITP) in childhood were published in 1992. Regional audit in 1995 showed substantial variation in clinical practice not related to clinical differences in patient groups, which indicated a need for national audit.
METHODS: Individuals aged from birth to their 16th birthday newly presenting with ITP were identified over 14 months by regular mailing of paediatricians and haematologists for case notification. Information was obtained from follow-up by a detailed questionnaire.
FINDINGS: ITP was clinically mild and benign in 323 (76%) of 427 cases, including 181 (70%) of 260 cases with platelet counts below 10 x 10(9)/L. There were no deaths or intracranial haemorrhages. There was a substantial discrepancy between clinical practice and published guidelines: many children were admitted to hospital and received treatment unnecessarily; there was overuse of intravenous immunoglobulin (IVIg) as first-line therapy (94 children); children received steroids without marrow examination; and there was inappropriate use of platelet transfusions (41 with mild or moderate disease).
INTERPRETATION: Our results indicate a need for change in practice.

Entities:  

Mesh:

Year:  1997        PMID: 9288044     DOI: 10.1016/s0140-6736(97)04143-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  26 in total

Review 1.  Systematic review of intravenous immunoglobulin in haemolytic disease of the newborn.

Authors:  R Gottstein; R W I Cooke
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2003-01       Impact factor: 5.747

Review 2.  Best practice in primary care pathology: review 3.

Authors:  W S A Smellie; J Forth; D Bareford; P Twomey; M J Galloway; E C M Logan; S R S Smart; T M Reynolds; C Waine
Journal:  J Clin Pathol       Date:  2006-08       Impact factor: 3.411

3.  Does treatment of newly diagnosed idiopathic thrombocytopenic purpura reduce morbidity?

Authors:  Iris Treutiger; Jukka Rajantie; Bernward Zeller; Jan-Inge Henter; Göran Elinder; Steen Rosthøj
Journal:  Arch Dis Child       Date:  2007-04-25       Impact factor: 3.791

4.  Immune thrombocytopenic purpura.

Authors:  V Gupta; V Tilak; B D Bhatia
Journal:  Indian J Pediatr       Date:  2008-08-21       Impact factor: 1.967

5.  MicroRNA-125-5p targeted CXCL13: a potential biomarker associated with immune thrombocytopenia.

Authors:  Jian-Qin Li; Shao-Yan Hu; Zhao-Yue Wang; Jing Lin; Su Jian; Yong-Chao Dong; Xiao-Fang Wu; Dai Lan; Li-Juan Cao
Journal:  Am J Transl Res       Date:  2015-04-15       Impact factor: 4.060

6.  Management of immune thrombocytopenic purpura: an update.

Authors:  Rajasekharan Warrier; Aman Chauhan
Journal:  Ochsner J       Date:  2012

Review 7.  Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review.

Authors:  C Neunert; N Noroozi; G Norman; G R Buchanan; J Goy; I Nazi; J G Kelton; D M Arnold
Journal:  J Thromb Haemost       Date:  2015-01-14       Impact factor: 5.824

8.  Association between drug and vaccine use and acute immune thrombocytopenia in childhood: a case-control study in Italy.

Authors:  Federica Bertuola; Carla Morando; Francesca Menniti-Ippolito; Roberto Da Cas; Annalisa Capuano; Giorgio Perilongo; Liviana Da Dalt
Journal:  Drug Saf       Date:  2010-01-01       Impact factor: 5.606

9.  Consensus Paper-ICIS Expert Meeting Basel 2009 treatment milestones in immune thrombocytopenia.

Authors:  Hannah Tamary; Jelena Roganovic; Meera Chitlur; Diane J Nugent
Journal:  Ann Hematol       Date:  2010-04-01       Impact factor: 3.673

10.  Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura.

Authors:  Cindy E Neunert; George R Buchanan; Paul Imbach; Paula H B Bolton-Maggs; Carolyn M Bennett; Ellis J Neufeld; Sara K Vesely; Leah Adix; Victor S Blanchette; Thomas Kühne
Journal:  Blood       Date:  2008-08-12       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.